PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Hepatology Research0 citations

Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study

View Full Paper
SKSatoru KakizakiTITadashi IkegamiTHTakeshi Hatanaka

Key Points

  • The study aims to evaluate the long-term effects of SOF/VEL therapy in patients with hepatitis C-related decompensated cirrhosis.
  • Retrospective multicenter cohort analysis
  • Assessment of sustained virologic response (SVR)
  • Evaluation of changes in the ALBI score
  • High rates of sustained virologic response (SVR) observed
  • Improvement in ALBI scores linked to better long-term prognosis in patients

Abstract

SOF/VEL therapy achieved high SVR rates and demonstrated that post-treatment improvement in the ALBI score is strongly associated with a favorable long-term prognosis in patients with decompensated cirrhosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kakizaki et al. (2026) studied this question.

synapsesocial.com/papers/69cf5ced5a333a821460a774https://doi.org/10.1111/hepr.70172
Ask AI
Helpful
Bookmark
Share
View Full Paper